Role of galectin-3 in diagnosis and severity assessment of epicardial artery lesions in patients with suspected coronary artery disease

BMC Cardiovascular Disorders

Research

Ivica Mihaljević¹  Ines Bilić-Ćurčić²  Dražen Bedeković³  Ivica Bošnjak³  Hrvoje Roguljić⁴  Kristina Selthofer-Relatić⁵ 

[1] Clinical Institute of Nuclear Medicine and Radiation Protection, University Hospital Centre Osijek, 31000, Osijek, Croatia;Department for Nuclear Medicine and Oncology, Faculty of Medicine, Josip Juraj Strossmayer University of Osijek, J. Huttlera 4, 31000, Osijek, Croatia;Academy of Medical Sciences of Croatia, Zagreb, Croatia;Department for Pharmacology, Faculty of Medicine, J. J. Strossmayer University of Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;Department of Endocrinology and Metabolism Disorders, Internal Medicine Clinic, University Hospital Centre Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Centre Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Centre Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;Department for Pharmacology, Faculty of Medicine, J. J. Strossmayer University of Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;Department of Pharmacology and Biochemistry, Faculty of Dental Medicine and Health Osijek, J. J. Strossmayer University of Osijek, 31000, Osijek, Croatia;Department of Cardiovascular Diseases, Internal Medicine Clinic, University Hospital Centre Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;Department of Pathophysiology, Faculty of Medicine, J. J. Strossmayer University of Osijek, J. Huttlera 4, 31 000, Osijek, Croatia;

关键词: Galectin-3;    Coronary artery disease;    Biomarker;    Chronic coronary syndrome;   

DOI  :  10.1186/s12872-023-03310-y

 received in 2022-09-26, accepted in 2023-05-17,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundThis study aimed to investigate the possible role of serum galectin-3 (Gal-3) levels in the diagnosis and assessment of significant epicardial artery lesions in patients with suspected coronary artery disease (CAD).MethodsThis was a single-center cross sectional cohort study including 168 subjects with suspected CAD and indications for coronary angiography divided into three groups: percutaneous coronary intervention (PCI) group (N 64), coronary artery bypass graft surgery (CABG) group (N 57), and group with no coronary stenosis (N 47). Gal-3 levels were measured and the syntax score (Ss) was calculated.ResultsThe mean value of Gal-3 in the PCI and CABG group was 19.98 ng/ml, while in the control group, it was 9.51 ng/ml (p < 0.001). The highest value of Gal-3 was found in the group of subjects with three-vessel disease (p < 0.001). When subgroups were analyzed by Gal-3 levels (< 17.8 ng/ml low, 18.8–25.9 ng/ml intermediate, > 25 ng/ml high risk) there was a significant difference between at least two Gal-3 groups for the arithmetic mean of Syntax score (p < 0.001). The syntax I’s arithmetic mean at low and intermediate-risk Gal-3 levels was significantly lower than at high-risk Gal-3 levels (p < 0.001).ConclusionGal-3 could be used as an additional tool for diagnosis and severity assessment of atherosclerotic disease in patients with suspected CAD. Furthermore, it could help identify high-risk subjects in patients with stable CAD.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

Fig. 1